本帖最后由 老马 于 2012-1-13 21:20 编辑
+ S: D1 ]: O3 j$ e
/ _9 a& {' }* A/ a$ o: N' M* y爱必妥和阿瓦斯丁的比较
8 I/ o7 _% C9 }: v
9 n2 a3 _+ s! hhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 b4 D: R6 _' d2 e' i: F
/ A! o: ]& ]- R3 D: u7 L
7 n* \, m# ?5 v* h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& _ k& m+ |/ Y$ {& G==================================================* b+ }0 Z* A; w, B1 H; E
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
`6 W4 `; Y6 G2 t$ F6 TPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 j; C, A$ W: M6 ^: p1 c( J. X- g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; E5 T) H1 l& |+ U
|